Form 4: Keros Therapeutics Director Carl Gordon Receives Significant Equity Awards, Bolstering Alignment with Shareholder Interests

Keros Therapeutics, Inc. Director Carl L. Gordon was granted 5,250 Restricted Stock Units and 10,500 stock options, aligning his compensation with the company's long-term performance.

Summary

• Carl L. Gordon, a Director of Keros Therapeutics, Inc. (KROS), was granted 5,250 Restricted Stock Units (RSUs) and 10,500 stock options on June 4, 2025.
• The RSUs were granted at a price of $0 and are set to fully vest on the earlier of June 4, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, contingent on Mr. Gordon's continued service.
• The stock options have an exercise price of $14.82 and will vest in equal quarterly installments over 12 months, fully vesting by the Issuer's 2026 annual meeting, also subject to continued service.
• Following these transactions, Mr. Gordon directly beneficially owns 5,250 shares of Common Stock and 10,500 stock options.
• Additionally, Mr. Gordon is indirectly associated with 899,212 shares held by OrbiMed Private Investments VII, LP and 119,522 shares held by OrbiMed Genesis Master Fund, L.P., through his role on the management committee of OrbiMed Advisors LLC, though he disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
• Mr. Gordon is obligated to transfer any securities or economic benefits received from these stock options or other awards to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will then provide them to OrbiMed Private Investments VII, LP.

Sentiment

Score: 7

Explanation: The sentiment is positive as it reflects standard and beneficial compensation practices that align a director's interests with the company's performance. The grants incentivize continued service and long-term value creation. The indirect ownership structure through OrbiMed is a common arrangement for fund representatives on boards.

Positives

• The grant of Restricted Stock Units and stock options to Director Carl L. Gordon aligns his personal financial interests with the long-term performance and shareholder value creation of Keros Therapeutics.
• Equity compensation is a standard practice that incentivizes directors to contribute to the company's success and strategic direction.
• The vesting schedules for both the RSUs and stock options encourage continued service and commitment from the director over the next year.

Negatives

• The obligation for the reporting person to transfer the economic benefit of the awards to OrbiMed entities, while aligning with fund interests, means the direct personal incentive for the individual director is channeled through the fund structure rather than directly held.

Risks

• The value of the equity awards is subject to the future market performance of Keros Therapeutics' common stock, meaning the actual realized value could be lower than the current implied value if the stock price declines.
• The vesting of both RSUs and stock options is contingent on the reporting person's continued service, posing a risk if service is terminated prior to full vesting.

Future Outlook

The equity awards granted to Director Carl L. Gordon are structured with vesting schedules extending to the company's 2026 annual meeting, indicating an expectation of his continued service and contribution to the company's strategic direction and performance over the coming year.

Industry Context

The granting of equity awards such as Restricted Stock Units and stock options is a common and widely accepted practice in the biotechnology and pharmaceutical industries for compensating directors and executives. This approach is designed to align the interests of company leadership with those of shareholders, incentivizing long-term growth and value creation. The specific structure involving OrbiMed entities reflects the common practice of venture capital or investment fund representatives serving on portfolio company boards and channeling their compensation through their respective funds.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is standard across the biotech and pharmaceutical sectors, comparable to practices at companies like Moderna, BioNTech, or Regeneron Pharmaceuticals, which frequently use equity to incentivize their leadership.
• The vesting schedule of approximately one year for full vesting of RSUs and quarterly vesting for options over 12 months is a common short-to-medium term incentive structure, often seen in early to mid-stage biotech companies to retain talent and align with near-term milestones.
• The exercise price of $14.82 for the options, if it represents the fair market value on the grant date, is typical for non-qualified stock options granted as compensation.

Corporate Governance

Related Party Transactions

• Carl L. Gordon is obligated to transfer any securities issued under the granted stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will then ensure such benefits are provided to OrbiMed Private Investments VII, LP. This constitutes a related party transaction given Mr. Gordon's role on the management committee of OrbiMed Advisors LLC.

Stakeholder Impact

• Shareholders: The equity awards align the director's interests with shareholder value creation, potentially leading to more focused efforts on company performance.
• Employees: No direct impact on employees is indicated, but a stable and incentivized board can contribute to overall company stability and success.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Continued service of Carl L. Gordon as a Director of Keros Therapeutics, Inc.
• Vesting of the 5,250 Restricted Stock Units on the earlier of June 4, 2026, or the 2026 annual meeting.
• Quarterly vesting of the 10,500 stock options over the next 12 months, with full vesting by the 2026 annual meeting.
• Potential exercise of stock options by the reporting person or transfer of economic benefit to OrbiMed entities upon vesting.

Key Dates

Keywords

Keros Therapeutics, KROS, SEC Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation, OrbiMed, Corporate Governance